FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Kim Na Yeon 2. Issuer Name and Ticker or Trading Symbol NeuroBo Pharmaceuticals, Inc. [ NRBO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)
C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY STREET, OFFICE 19TH FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)
7/26/2022
(Street)
BOSTON, MA 02116
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  7/26/2022    J(1)    1445267  D $0  2890533  I  Held by The E&Healthcare Investment Fund II (2)
Common Stock                 1121190  I  Held by The E&Healthcare Investment Fund No. 6 (2)
Common Stock                 1864799  I  Held by The E&Healthcare Investment Fund No. 7 (2)
Common Stock                 43796 (3) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  E&Healthcare Investment Fund II distributed 1,445,267 shares to its partners on a pro rata basis, for no consideration.
(2)  Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.
(3)  Ms. Kim received a pro rata distribution from E&Healthcare Investment Fund II, of which she is a limited partner.

Remarks:
Exhibit 24, Power of Attorney, is attached.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Kim Na Yeon
C/O NEUROBO PHARMACEUTICALS, INC.
200 BERKELEY STREET, OFFICE 19TH FLOOR
BOSTON, MA 02116
X X


Signatures
/s/ Phillip D. Torrence, by Power of Attorney 7/28/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more NeuroBo Pharmaceuticals Charts.
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more NeuroBo Pharmaceuticals Charts.